Vincent S. Beltrani, MD, FAAAAI
1 / 9

Vincent S. Beltrani - PowerPoint PPT Presentation

  • Uploaded on

Vincent S. Beltrani, MD, FAAAAI Board Certified by American Academy of Dermatology American Academy Allergy, Asthma & Immunology. Associate Clinical Professor Department of Dermatology Department of Allergy Columbia University UMDNJ

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Vincent S. Beltrani' - liam

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Vincent S. Beltrani, MD, FAAAAIBoard Certified byAmerican Academy of DermatologyAmerican Academy Allergy, Asthma & Immunology

Associate Clinical Professor

Department of Dermatology Department of Allergy

Columbia University UMDNJ

New York, New York Newark, New Jersey

Atopic dermatitis is the dermatologic syndrome that frequently heralds the atopic diathesis
Atopic dermatitis is the dermatologic syndrome that frequently heralds theAtopic Diathesis

Atopic dermatitis
Atopic dermatitis frequently heralds the

  • The earlier the onset, the more severe the dermatitis.

  • 70% of patients with severe AD developed asthma compared with 30% of patients with mild AD, and approx. 8% in general population.

  • Therapies that modify the severity of AD in infants and young children might decrease the risk of the eventual development of asthma.

Aad guidelines jaad 2004 50 391 400 topical corticosteroids
AAD Guidelines frequently heralds theJAAD 2004;50:391-400Topical corticosteroids

  • Topical CS remain the standard of care.

  • Recognize complications – striae, atrophy, telengectasia, limit use.

  • Limited data re: optimal concentrations, duration and frequency of Rx, quantity of application, etc.

  • Effect and absorption by hydration &/or occlusion.

  • Tachyphylaxis (not documented)

  • Long-term intermittent use – helpful & safe.

Risk factors of topical steroids
Risk factors of Topical Steroids frequently heralds the

  • “Steroid phobia”

  • Atrophogenicity (essentially to potent CS)

  • Acne/rosacea-genicity

  • Allergic Contact Dermatitis (nonhalogenated >>halogenated CS

  • (?)Tachyphylaxis

  • Systemic absorption “Immunosuppression” Hypoadrenalism

Atopic dermatitis long term management

Onset of Itching/pruritus frequently heralds the

or signs of inflammation

Severe flare-up

Dry skin




Calcineuron Inhibitors


Atopic Dermatitis Long-Term Management

Disease severity


Aad guidelines topical calcineuron inhibitors
AAD Guidelines frequently heralds theTopical Calcineuron Inhibitors

  • CI’s are safe and effective in reducing the severity of AD symptoms in children and adults.

  • CI’s have favorable safety profiles for up to one year of continued use. (Expert Opinion on Drug Safety 2(5):457, 2003)

Aaaai disease management of ad annals allergy asthma immunol 2004 93s2
AAAAI frequently heralds theDisease Management of AD(Annals Allergy Asthma Immunol 2004;93S2.)

  • Short-term, multicenter, blinded, vehicle- controlled studies with pimecrolimus cream 1% patients with AD have shown pimecrolimus to be both effective and safe.

  • Pimecrolimus cream 1% has been approved for short-term and intermittent long-term use in patients with mild-to-moderate AD who are 2 years and older.

Recommendation of the college of allergy
Recommendation of the frequently heralds theCollege of Allergy

  • From our experience with the “negative effect” by the existing steroid-phobia, the addition of a possible “black box” warning to the label of Elidel, will result in less aggressive treatment for some patients with AD, who will then be denied effective intervention to control their atopic march.